Xê-mi-na khoa học
10/01/2023: Dr. Luu Phuc Loi (Pacific Informatics, Vietnam), Epigenomics in clinical applications
More and more genetic and genomic testing are developed and approved to be used in clinic after human genome project finished in 2001. With the emerging of NGS in 2005, the genetic and genomic testing is further advanced and plays an important role in clinical diagnosis and prognosis. Were born later, epigenetic and epigenomic testing are still unmature and in development phase. However, there are a few tests available for several cancers in oncology hospitals. These tests are not only for pronosis and diagnosis but also for monitoring the treatments. In this presentation, Loi will share the journey of development clinical epigenetic (DNA methylation) markers including tissue and liquid biopsy in some cancers and infection disease. In addition, Loi will also show some data of pharmaco-epigenomics in treatment of breast cancer using epigenetics drugs.
Speaker: TS. TLưu Phúc Lợi, Pacific Informatics, Vietnam
Time: 3:30-4:30pm, Tuesday, January 10, 2023
Venue: Webinar; Access code: https://bit.ly/3QcEs21
Dr. Loi is a Bioinformatics Team Leader at Pacific Informatics, Vietnam. Dr. Loi has been working as a medical researcher at Garvan Institute of Medical Research, Sydney, Australia since 2014. He has developed a long-term interest in clinical epigenetics and genomics using the next-generation sequencing (NGS) technologies since his Bioinformatics Master training at the Max Planck Institute for Informatics and doctoral at the Max Planck Institute for Molecular Biomedicine, Germany during 2008 – 2014. Based on the NGS, Loi has built multiple bioinformatics tools and wet-let protocols for a wide range of studies from mechanism studies to translational research. After moving to Garvan, Loi established his own research topic on translational studies including pharmaco-epigenomics and epigenetics biomarker development for prognosis, diagnosis and disease progression monitoring in breast, prostate cancer, and rare genetic diseases. He has (co)-authored several publications in high impact factor journals such as Nature communications, Cancer cell, Clinical and Translational Medicine, Genome Research.